Please login to Zacks.com or register to post a comment.
| No Recent Quote currently available |
|
My Portfolio Tracker One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today. |
Zacks Rank Home - Evaluate your stocks and use the Zacks Rank to eliminate the losers and keep the winners.
Mutual Fund Rank Home - Evaluate your funds with the Mutual Fund Rank for both your personal and retirement funds.
Stock/Mutual Fund Screening - Find better stocks and mutual funds. The ones most likely to beat the market and provide a positive return.
My Portfolio - Track your Portfolio and find out where your stocks/mutual funds stack up with the Zacks Rank.
| Company Name | Symbol | %Change |
|---|---|---|
| SCIENTIFIC L | SCIL | 8.00% |
| NATUS MEDICA | BABY | 6.11% |
| SUMMER INFAN | SUMR | 6.02% |
| RADIANT LOGI | RLGT | 5.32% |
| NEW ORIENTAL | EDU | 4.51% |
Please login to Zacks.com or register to post a comment.
Resources
Client Support
Zacks Research is Reported On:
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This page is temporarily not available. Please check later as it should be available shortly. If you have any questions, please email customer support at support@zacks.com or call 800-767-3771 ext. 9339.
We are downgrading StanCorp Financial Group Inc. ( SFG - Analyst Report ) to ‘Underperform’ from ‘Neutral’, following the company’s announcement to post lower earnings in the second quarter. The company expects earnings to be $0.51 per share, hurt by lower favorable claims experience in the group long-term disability insurance business. The Zacks Consensus Estimate is currently pegged at $0.85.
StanCorp expects second quarter adjusted earnings to decline 13.5% year over year. The earnings will be hurt by less favorable claims experience in the group long-term disability insurance business. It also expects to deliver higher benefit ratio for its group insurance products. It is expected to be 88.5%, exceeding the guided range of 80% to 82% for 2012. The company also expects to incur after-tax net capital losses of $0.06 per share in the second quarter. Taking this into account, net income is expected to be $0.45 per share, representing a year-over-year improvement of 12.5%. Given the performance in the first half of 2012, it now expects to fall short of its full year guidance of $3.60–$3.90 per share.
Rating affirmations or upgrades from credit rating agencies play an important part in retaining investor confidence in the stock as well as maintaining creditworthiness in the market. A rating downgrade therefore, adversely affects the business, besides increasing cost of future debt issuances. Moody’s downgraded the financial strength and credit ratings for the company and its subsidiaries. However, recently another rating agency, Fitch Ratings, affirmed the long-term issuer default rating with a stable outlook.
Also, StanCorp’s Asset Management segment, after posting solid earnings over the past couple of quarters, witnessed a decline for the third consecutive quarter, mainly driven by lower bond call premium. Further, assets under administration in the retirement plans business showed a sequential decline. Low interest rate environment continues to weigh on the company’s long-term disability claim reserves in Group Insurance Business.
Counting on the positives, StanCorp, for the third consecutive time reported lower delinquency. This also marks the lowest 60 day delinquency rate since the first quarter of 2009.
StanCorp has an excellent underwriting track record in its core employee benefits business. Given its pricing policies and underwriting efforts, the company’s reserves improved by 4.2% over the last-year quarter to $111.7 million in the first quarter of 2012.
The company also enjoys a strong capital position. The risk-based capital ratio at its insurance subsidiaries was 300% as of March 31. As of March 31, StanCorp had approximately 3.0 million shares remaining under its repurchase authorization. It stated that an amount of $20 million of the capital have been set aside for the purpose of dividend payment. The company also expects to buyback shares in the band of $40 million to $80 million in 2012.
The quantitative Zacks #5 Rank (short-term Hold rating) for the company indicates downward pressure on the stock over the near term. Metlife Inc. ( MET - Analyst Report ) and Unum Group ( UNM - Analyst Report ) , which compete with Stancorp, both hold a quantitative Zacks #3 Rank (short-term Hold rating), indicating no clear directional pressure on the stock over the near term. Another peer, Principal Financial Group Inc. ( PFG - Analyst Report ) , holds a quantitative Zacks #4 Rank (short-term Sell rating) indicating slight downward pressure on the stock over the near term.
Read the full reports :
Analyst Report on MET
Analyst Report on SFG
Analyst Report on PFG
Analyst Report on UNM